Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020 07:01 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer
September 24, 2020 07:00 ET
|
Calithera Biosciences, Inc.
- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting among patients with non-small cell lung cancer and a mutation...
Calithera to Participate in Multiple Upcoming Investor Conferences
September 04, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2020 07:01 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
August 10, 2020 16:06 ET
|
Calithera Biosciences, Inc.
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences,...
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2020 07:01 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
July 28, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Appoints Scott Garland to Board of Directors
July 14, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences announced today the appointment of Scott Garland to its board of directors. Garland is a 29-year veteran of the...
Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
July 13, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule...
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2020 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...